{"protocolSection": {"identificationModule": {"nctId": "NCT00503009", "orgStudyIdInfo": {"id": "HZA109895"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Study Of RV-39 In Patients Who Also Have Asthma", "officialTitle": "An Exploratory Study to Evaluate the Response of Salmeterol Plus Fluticasone vs Fluticasone Alone to Experimental Nasal Inoculation With Rhinovirus"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "TERMINATED", "whyStopped": "lack of data", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-10"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-07-17", "studyFirstSubmitQcDate": "2007-07-17", "studyFirstPostDateStruct": {"date": "2007-07-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-07-06", "resultsFirstSubmitQcDate": "2009-07-06", "resultsFirstPostDateStruct": {"date": "2009-08-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-04", "lastUpdatePostDateStruct": {"date": "2016-12-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Subjects will inhale an FDA approved virus through their nose which is known to cause the common cold. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Rhinovirus", "Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 16, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm 1", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: fluticasone propionate/salmeterol"]}, {"label": "Arm 2", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: fluticasone propionate"]}, {"label": "Arm 3", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "fluticasone propionate/salmeterol", "description": "comparator", "armGroupLabels": ["Arm 1"], "otherNames": ["fluticasone propionate"]}, {"type": "DRUG", "name": "fluticasone propionate", "description": "Comparator", "armGroupLabels": ["Arm 2"]}, {"type": "DRUG", "name": "placebo", "description": "Placebo", "armGroupLabels": ["Arm 3"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in the Cumulative Lower Respiratory Symptom Score Averaged Over Days 1-4", "description": "The cumulative lower respiratory symptom score consisted of the summary of individual scores assessing cough, shortness of breath, chest discomfort, and wheezing based on the following scale: 0 (not present); 1=mild, clearly present; 2=moderately severe, uncomfortable; 3=severe (best possible score of 12; worst possible score of 0), interfering with sleep or activity. Due to the small sample size, efficacy measures were not analyzed.", "timeFrame": "Days 1 through 4"}], "secondaryOutcomes": [{"measure": "Change From Baseline in the Morning Peak Expiratory Flow (PEF) Averaged Over Days 1-4", "description": "PEF measurements were collected via a study-issued electronic peak flow meter. Due to the small sample size, efficacy measures were not analyzed.", "timeFrame": "Days 1 through 4"}, {"measure": "Change From Baseline in the Morning Forced Expiratory Volume in One Second (FEV1) Averaged Over Days 1-4", "description": "FEV1 measurements were collected via a study-issued spirometer. Due to the small sample size, efficacy measures were not analyzed.", "timeFrame": "Days 1 through 4"}, {"measure": "Change From Baseline in Exhaled Nitric Oxide (eNO) Averaged Over Days 1-4", "description": "eNO was measured using a study-issued monitor. Due to the small sample size, efficacy measures were not analyzed.", "timeFrame": "Days 1 through 4"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have asthma for at least 3 months prior to the study.\n* Have been using an allowed pre-study asthma therapy for at least 3 months prior to study.\n* Demonstrate airway hyperresponsiveness following inhalation of bronchoconstrictor.\n* Have a positive allergic status antibody test.\n\nExclusion Criteria:\n\n* Have a history of life-threatening asthma.\n* Been hospitalized for asthma within the 24 months prior to the study.\n* Have certain conditions that would make study participation unsafe.\n* The study doctor will evaluate other inclusion and exclusion criteria.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "40 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Charlottesville", "state": "Virginia", "zip": "22908", "country": "United States", "geoPoint": {"lat": 38.02931, "lon": -78.47668}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "HZA109895", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109895", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109895", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109895", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109895", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109895", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Eligible subjects were randomized to one of two sputum induction groups (sputum induction, no sputum induction) and then stratified at a second randomization to one of three treatment groups (Fluticasone Propionate/Salmeterol \\[FSC 250/50\\] mcg twice a day \\[BID\\], Fluticasone Propionate \\[FP\\] 250 mcg BID, or Placebo BID).", "groups": [{"id": "FG000", "title": "FSC 250/50 mcg BID", "description": "Fluticasone Propionate/Salmeterol (FSC) (250/50 microgram) twice daily"}, {"id": "FG001", "title": "FP 250 mcg BID", "description": "Fluticasone Propionate (FP) (250 microgram) twice daily"}, {"id": "FG002", "title": "Placebo Diskus BID", "description": "Placebo twice daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "FSC 250/50 mcg BID", "description": "Fluticasone Propionate/Salmeterol (FSC) (250/50 microgram) twice daily"}, {"id": "BG001", "title": "FP 250 mcg BID", "description": "Fluticasone Propionate (FP) (250 microgram) twice daily"}, {"id": "BG002", "title": "Placebo Diskus BID", "description": "Placebo twice daily"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "16"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20.4", "spread": "2.07"}, {"groupId": "BG001", "value": "20.0", "spread": "1.00"}, {"groupId": "BG002", "value": "23.0", "spread": "5.83"}, {"groupId": "BG003", "value": "21.25", "spread": "3.8"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "11"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "11"}]}]}, {"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}]}]}, {"title": "American Indian/Alaskan Native/Native Hawaiian/Pac", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in the Cumulative Lower Respiratory Symptom Score Averaged Over Days 1-4", "description": "The cumulative lower respiratory symptom score consisted of the summary of individual scores assessing cough, shortness of breath, chest discomfort, and wheezing based on the following scale: 0 (not present); 1=mild, clearly present; 2=moderately severe, uncomfortable; 3=severe (best possible score of 12; worst possible score of 0), interfering with sleep or activity. Due to the small sample size, efficacy measures were not analyzed.", "reportingStatus": "POSTED", "timeFrame": "Days 1 through 4", "groups": [{"id": "OG000", "title": "FSC 250/50 mcg BID", "description": "Fluticasone Propionate/Salmeterol (FSC) (250/50 microgram) twice daily"}, {"id": "OG001", "title": "FP 250 mcg BID", "description": "Fluticasone Propionate (FP) (250 microgram) twice daily"}, {"id": "OG002", "title": "Placebo Diskus BID", "description": "Placebo twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Morning Peak Expiratory Flow (PEF) Averaged Over Days 1-4", "description": "PEF measurements were collected via a study-issued electronic peak flow meter. Due to the small sample size, efficacy measures were not analyzed.", "reportingStatus": "POSTED", "timeFrame": "Days 1 through 4", "groups": [{"id": "OG000", "title": "FSC 250/50 mcg BID", "description": "Fluticasone Propionate/Salmeterol (FSC) (250/50 microgram) twice daily"}, {"id": "OG001", "title": "FP 250 mcg BID", "description": "Fluticasone Propionate (FP) (250 microgram) twice daily"}, {"id": "OG002", "title": "Placebo Diskus BID", "description": "Placebo twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Morning Forced Expiratory Volume in One Second (FEV1) Averaged Over Days 1-4", "description": "FEV1 measurements were collected via a study-issued spirometer. Due to the small sample size, efficacy measures were not analyzed.", "reportingStatus": "POSTED", "timeFrame": "Days 1 through 4", "groups": [{"id": "OG000", "title": "FSC 250/50 mcg BID", "description": "Fluticasone Propionate/Salmeterol (FSC) (250/50 microgram) twice daily"}, {"id": "OG001", "title": "FP 250 mcg BID", "description": "Fluticasone Propionate (FP) (250 microgram) twice daily"}, {"id": "OG002", "title": "Placebo Diskus BID", "description": "Placebo twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Exhaled Nitric Oxide (eNO) Averaged Over Days 1-4", "description": "eNO was measured using a study-issued monitor. Due to the small sample size, efficacy measures were not analyzed.", "reportingStatus": "POSTED", "timeFrame": "Days 1 through 4", "groups": [{"id": "OG000", "title": "FSC 250/50 mcg BID", "description": "Fluticasone Propionate/Salmeterol (FSC) (250/50 microgram) twice daily"}, {"id": "OG001", "title": "FP 250 mcg BID", "description": "Fluticasone Propionate (FP) (250 microgram) twice daily"}, {"id": "OG002", "title": "Placebo Diskus BID", "description": "Placebo twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "FSC 250/50 mcg BID", "description": "Fluticasone Propionate/Salmeterol (FSC) (250/50 microgram) twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 2, "otherNumAtRisk": 5}, {"id": "EG001", "title": "FP 250 mcg BID", "description": "Fluticasone Propionate (FP) (250 microgram) twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 1, "otherNumAtRisk": 5}, {"id": "EG002", "title": "Placebo Diskus BID", "description": "Placebo twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 0, "otherNumAtRisk": 6}], "otherEvents": [{"term": "Heartburn", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 6}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 6}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 6}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Due to the small sample size, efficacy measures were not analyzed."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}